Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.137 CHF
−63.04 M CHF
145.48 M CHF
251.14 M
About Akebia Therapeutics, Inc.
Sector
Industry
CEO
John P. Butler
Website
Headquarters
Cambridge
Founded
2007
ISIN
US00972D1054
FIGI
BBG00LVD5GC6
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of AX9 is 2.104 CHF — it has increased by 66.85% in the past 24 hours. Watch Akebia Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange Akebia Therapeutics, Inc. stocks are traded under the ticker AX9.
We've gathered analysts' opinions on Akebia Therapeutics, Inc. future price: according to them, AX9 price has a max estimate of 8.07 CHF and a min estimate of 4.84 CHF. Watch AX9 chart and read a more detailed Akebia Therapeutics, Inc. stock forecast: see what analysts think of Akebia Therapeutics, Inc. and suggest that you do with its stocks.
AX9 stock is 40.07% volatile and has beta coefficient of 0.69. Track Akebia Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Akebia Therapeutics, Inc. there?
Today Akebia Therapeutics, Inc. has the market capitalization of 580.04 M, it has increased by 6.12% over the last week.
Yes, you can track Akebia Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Akebia Therapeutics, Inc. is going to release the next earnings report on Nov 6, 2025. Keep track of upcoming events with our Earnings Calendar.
Akebia Therapeutics, Inc. revenue for the last quarter amounts to 49.57 M CHF, despite the estimated figure of 37.48 M CHF. In the next quarter, revenue is expected to reach 41.56 M CHF.
AX9 net income for the last quarter is 195.97 K CHF, while the quarter before that showed 5.41 M CHF of net income which accounts for −96.38% change. Track more Akebia Therapeutics, Inc. financial stats to get the full picture.
No, AX9 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 30, 2025, the company has 181 employees. See our rating of the largest employees — is Akebia Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Akebia Therapeutics, Inc. EBITDA is 19.31 M CHF, and current EBITDA margin is −5.44%. See more stats in Akebia Therapeutics, Inc. financial statements.
Like other stocks, AX9 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Akebia Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.